Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA COVID-19 vaccine
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The mRNA COVID-19 vaccines, specifically BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna), are lipid nanoparticle-encapsulated mRNA therapies designed to prevent COVID-19 by inducing an immune response against the SARS-CoV-2 spike protein. In the context of the COVER (COVID-19 VaccinE Response in Rheumatology patients) trial, these vaccines were evaluated as booster doses in patients with autoimmune rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. The study, led by Dr. Jeffrey Curtis at the University of Alabama at Birmingham, specifically investigated whether a temporary two-week interruption of immunomodulatory treatments (e.g., TNF inhibitors, JAK inhibitors, or abatacept) at the time of vaccination could improve the magnitude of the antibody response without causing significant disease flares.
- Brand names
- ComirnatySpikevax
- Other names
- mRNA COVID-19 vaccine-Jeffrey Curtis-COVID-19Pfizer-BioNTech COVID-19 vaccineModerna COVID-19 vaccinemRNA COVID-19 booster
02
Targets
ACE2 (Angiotensin-converting enzyme 2)IFIH1 (MDA5)SARS-CoV-2 spikeITGA5:ITGB1 (Integrin α5β1)
Beyond the preview
Go deeper on mRNA COVID-19 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA COVID-19 vaccine.